Abeona Therapeutics Inc.

NASDAQ:ABEO

Biotechnology

Healthcare
$2.73 +1.06%

+$0.06 today

Market cap
$156.01M
Beta
1.35
P/E (TTM)
4.9
EPS (TTM)
$1.17
52W Low $4.00High $7.54

Volume 1.71M

Average 1.12M

ABEO EBITDA Margin

EBITDA as a percentage of revenue.

Abeona Therapeutics Inc.NASDAQ: ABEO

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin at -176.3%

EBITDA Margin was -176.3% in Q1 FY2026. On a trailing-twelve-month basis it was 505.0%. Over 3 fiscal years it widened by 3781.9 pp.

Context

  • EBITDA Margin widened in 2 of the last 2 fiscal years.
  • FY2025 was the highest level in the 3 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -109.6% for the fiscal year ending Dec 2026, down from 1350.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-176.3%+168.7 pp QoQ
Last fiscal yearDec 2025
1350.3%— YoY
LTMMar 2026
505.0%— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter—-31614.5 pp—
1 year—-1459.9 pp—
3 years+3781.9 pp-1331.3 pp-5113.2 pp
5 years-1284.9 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
1350.3%
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ABEO compares with its peers on the latest reported figures

  • ABEO's LTM Mar 2026 EBITDA Margin of 505.0% is the highest of the 8 companies compared; the peer median is -257.0%.
  • Over three fiscal years its change of +3781.9 pp compares with a peer median of -100.7 pp.
ABEO Competitors Peer median
EBITDA Margin for ABEO and competitors
Company Period LTM level YoY 3-year change
ABEOAbeona Therapeutics Inc.LTM Mar 2026505.0% —+3781.9 pp
PBYIPuma Biotechnology, Inc.LTM Mar 202619.8% -3.7 pp+13.8 pp
ASMBAssembly Biosciences, Inc.LTM Mar 2026-8.8% +113.4 pp—
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-148.9% -100.7 pp-100.7 pp
FHTXFoghorn Therapeutics Inc.LTM Mar 2026-257.0% +77.3 pp+319.4 pp
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-308.4% -186.1 pp-189.2 pp
HUMAHumacyte, Inc.LTM Mar 2026-3956.7% -3182.9 pp-1247.4 pp
TNYATenaya Therapeutics, Inc.LTM Mar 2026-33540.9% ——
SGMTSagimet Biosciences Inc.FY2025— ——
ELDNEledon Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding ABEO) -257.0%-52.2 pp-100.7 pp

Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3M1.41M3.5M05.82M
Cost of Revenue0450K1.61M2.91M1.53M
Gross Profit3M964K1.9M(2.91M)4.29M
Gross Margin100.0%68.2%54.1%—73.7%
Research & Development38.73M28.97M31.09M34.36M26.81M
Selling, General & Admin21.64M17.26M19M29.85M65.03M
Operating Expenses92.84M51.88M49.03M61.3M93.74M
Depreciation & Amortization4.46M4.58M3.2M2.91M3.56M
EBITDA(76.82M)(34.38M)(50.57M)(56.62M)78.59M
EBITDA Margin-2560.5%-2431.6%-1444.9%—1350.3%
Operating Income(89.84M)(50.92M)(47.14M)(64.21M)(89.45M)
Operating Margin-2994.5%-3600.8%-1346.7%—-1536.9%
Interest Income40K431K2.12M4.25M5.56M
Interest Expense3.66M736K418K4.21M3.74M
Other Income / Expenses4.9M11.22M(7.05M)477K160.73M
Income Before Tax(84.94M)(39.7M)(54.19M)(63.73M)71.28M
Pre-Tax Margin-2831.2%-2807.4%-1548.2%—1224.8%
Income Tax Expense0000100K
Net Income(84.94M)(39.7M)(54.19M)(63.73M)71.18M
Net Margin-2831.2%-2807.4%-1548.2%—1223.1%
EPS (Basic)(21.50)(5.53)(2.53)(1.55)1.34
EPS (Diluted)(21.50)(5.53)(2.53)(1.55)1.01
Weighted Avg Shares3.94M7.86M21.38M41.05M52.95M
Weighted Avg Shares (Diluted)3.94M7.86M21.38M41.05M66.14M

Abeona Therapeutics Inc.

NASDAQ:ABEO

Intrinsic Alpha fair value

Locked

Current Price

$2.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.